Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study

Takahashi, Hiroyuki

Oral and Poster Abstracts
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II

Acute Myeloid Malignancies, APL, Combination therapy, Diseases, Myeloid Malignancies

Hiroyuki Takahashi, MD, PhD¹^*, Shiro Tanaka, PhD²^*, Yuki Yuza, MD, PhD³^*, Yuka Iijima-Yamashita, PhD⁴^*, Daisuke Hasegawa, MD, PhD⁵^*, Hiroshi Moritake, MD, PhD⁶, Kiminori Terui, MD, PhD⁷^*, Shotaro Iwamoto, MD⁸^*, Akira Shimada, MD, PhD⁹, Jun Matsubayashi, PhD¹⁰^*, Takao Deguchi, MD, PhD¹¹, Yoshiko Hashii, MD, PhD¹², Nobutaka Kiyokawa, MD, PhD¹³^*, Hayato Miyachi, MD, PhD¹⁴^*, Akiko Moriya Saito, MD, PhD¹⁵^*, Takashi Taga, MD, PhD¹⁶^*, Souichi Adachi, MD, PhD¹⁷ and Daisuke Tomizawa, MD, PhD¹⁸

¹Department of Pediatrics, Toho University, Tokyo, Japan
²Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
³Department of Hematology-Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan
⁴Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi, JPN
⁵Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan
⁶Division of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
⁷Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
⁸Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan
⁹Department of Pediatrics, Jichi Medical University Hospital, Tochigi, Japan
¹⁰Center for Clinical Research and Advanced Medicine, Shiga University of Medical Science, Otsu, Japan
¹¹Division of Cancer Immunodiagnostics, Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan
¹²Department of Pediatrics, Osaka International Cancer Institute, Osaka, Japan
¹³Department of Pediatric Hematology and Oncology Research, Research Institute, National Center for Child Health and Development, Tokyo, Japan
¹⁴Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan
¹⁵Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
¹⁶Department of Pediatrics, Shiga University of Medical Science, Otsu, Japan
¹⁷Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
¹⁸Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan

Aims:

Arsenic trioxide (ATO) has shown to be effective in patients with acute promyelocytic leukemia (APL), which has led to a dose reduction of cytotoxic agents in the treatment of APL. To investigate safety and efficacy of ATO in Japanese children with APL, we conducted a nationwide prospective study, JPLSG AML-P13 (jRCTs051180191).

Patients & Methods:

Between December 2014 and November 2018, children (0-18 years old) with newly diagnosed APL were enrolled in the AML-P13 study. All patients received two courses of induction therapy consisting of ATRA, cytarabine, and daunorubicin. Patients who achieved hematological complete remission (HCR) were allocated to the standard risk (SR) group and received three intensification cycles consisting of ATRA and ATO, followed by intermittent ATRA maintenance therapy. Patients who did not obtain HCR after induction courses were allocated to the high risk (HR) group and received intensified schedule of ATO, followed by gemtuzumab ozogamicin monotherapy and maintenance therapy consisting of 6-mercaptopurine and methotrexate.

Results & Discussions:

Among the 32 patients registered, 5 patients were excluded due to a lack of PML::RARA fusion or other reasons, and the remaining 27 patients received the protocol therapy (full analysis set). During induction courses, grade 3 disseminated intravascular coagulation was observed in 9 patients (33.3%). APL differentiation syndrome and induction death were not reported. Two patients were taken off protocol therapy due to a progressive disease (regarded as an event) and a safety issue, respectively. Among the 25 patients who completed induction therapy, 23 patients obtained HCR. During intensification cycles of ATO, grade 3 or higher non-hematological adverse events (AEs) were observed in 3 patients: prolonged QTc interval in 2 and dysesthesia in one. Regarding hematological AEs, 10 to 30% patients exhibited grade 4 neutropenia during each intensification cycles, but no patients experienced severe infectious complications. Two patients who did not obtain HCR received HR regimen without any apparent AEs. All 25 patients including 2 HR patients achieved molecular remission at the end of intensification and molecular remission rate was 100.0% [95% C.I. 86.3-100.0%]. No patients suffered from relapse, and 3-year EFS rate and 3-year OS rate in full analysis set were 96.3% [76.5-99.5%] (Figure) and 100.0% [87.2-100.0%], respectively. We previously reported an inferior outcome of younger children (less than 5 years old) treated with conventional ATRA and chemotherapy in the JPLSG AML-P05 study (Takahashi H. Br J Haematol 2016). However, 4 children under 5 years of age at diagnosis in the AML-P13 study remains in molecular remission, indicating efficacy of ATO in this age group of children.

Interpretations:

The AML-P13 study demonstrated an excellent outcome in children with APL and showed that ATO could be administered safely in children with APL.

Disclosures: Tomizawa: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

See more of: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
See more of: Oral and Poster Abstracts

<< Previous Abstract | Next Abstract >>

^*signifies non-member of ASH

2742 Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study